Alimera Sciences announced that four Iluvien data sets will be presented during the 2017 Annual Meeting of the Retina Society to be held October 5-8 at the Fairmont Copley Plaza Hotel in Boston.
"We are excited to see new data and analysis from both real world clinical experience and our pivotal FAME Study being presented at the Retina Society this year. We believe the new data being presented validates the key value of Iluvien’s continuous microdosing and unique ability to treat diabetic macular edema consistently every day," Dan Myers, CEO of Alimera, said in a company news release. "We are particularly gratified to share data from the USER (U.S. Retrospective Chart Review in Patients Receiving Iluvien) Study as it demonstrates Iluvien’s ability to provide maintained or improved visual acuity with a reduced treatment frequency and the effectiveness of the U.S. label to help physicians mitigate intraocular pressure responses."
Scheduled to be presented at the podium are:
- Thursday, Oct. 5 – 4:55 p.m. – “Area Under the Curve (AUC) Analysis of Visual Outcomes with the Fluocinolone Acetonide Implant and with Ranibizumab and Deferred Laser Over 36 Months,” by Craig Greven, MD.
- Sunday, Oct. 8 – 8:10 a.m. – “Real World Outcomes with the Fluocinolone Acetonide (FAc) 0.2 g/day Implant for Diabetic Macular Edema: The USER Study,” by Christopher Riemann, MD.
The following two posters are included in Poster Session II – Saturday, Oct. 7, 1:15 PM – 2:15 p.m.:
- “Year 3 Visual Acuity Response in Early Nonresponders to 0.2 ug/day Fluocinolone Acetonide Implants: FAME Study Post Hoc Analysis,” by Daniel Kiernan, MD.
- “Fluocinolone Acetonide Intravitreal Implant in Treatment Experienced Eyes for Diabetic Macular Edema (DME): One-year Results,” by Sumit Shah, MD.